2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 05, 2020 |
Jan. 31, 2020 |
Oct. 31, 2019 |
Aug. 12, 2019 |
Jul. 31, 2019 |
Jan. 31, 2019 |
Oct. 31, 2018 |
Jul. 31, 2018 |
Jan. 31, 2020 |
Jan. 31, 2019 |
Apr. 30, 2019 |
|
| Intangible assets | $ 3,549,427 | $ 3,549,427 | $ 3,549,427 | ||||||||
| Impairment of intangible assets | 0 | $ 0 | |||||||||
| Impairment of long-lived assets | $ 0 | 0 | |||||||||
| U.S. federal income tax rate | 21.00% | ||||||||||
| Research and development costs | 113,296 | $ 59,144 | $ 203,566 | 442,039 | |||||||
| Uninsured cash balances | 0 | 0 | 127,000 | ||||||||
| Accumulated deficit | (103,107,876) | (103,107,876) | $ (100,031,371) | ||||||||
| Net loss | (875,308) | $ (1,067,122) | $ (1,134,075) | $ (676,347) | $ (1,036,574) | $ (1,215,363) | (3,076,505) | $ (2,928,284) | |||
| Block Trade [Member] | |||||||||||
| Proceeds from the sale of equity | $ 884,000 | ||||||||||
| Block Trade [Member] | Subsequent Event [Member] | |||||||||||
| Proceeds from the sale of equity | $ 186,000 | ||||||||||
| Private Placement [Member] | |||||||||||
| Proceeds from the sale of equity | 450,000 | ||||||||||
| Private Placement [Member] | Subsequent Event [Member] | |||||||||||
| Proceeds from the sale of equity | $ 65,000 | ||||||||||
| Cell-in-a-Box [Member] | |||||||||||
| Intangible assets | 1,549,427 | 1,549,427 | |||||||||
| Diabetes License [Member] | |||||||||||
| Intangible assets | $ 2,000,000 | $ 2,000,000 | |||||||||
| SG Austria [Member] | |||||||||||
| Percentage investment in SG Austria | 14.50% | 14.50% | |||||||||
| X | ||||||||||
- Definition The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation. No definition available.
|
| X | ||||||||||
- Definition Percentage of domestic federal statutory tax rate applicable to pretax income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill. No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Percent of net assets at close of period. For schedules of investments that are categorized, each category has a percent of net assets for the aggregated value of the Investments in the category. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|